Dr. Mahvish Muzaffar, MD

Dr. Muzaffar practices at ECU Health Medical Center in Greenville, North Carolina, part of University Health Systems of Eastern Carolina.

Dr. Muzaffar's NPI, 1720244734, was assigned on July 30, 2008. Dr. Muzaffar holds North Carolina license 2013-01278.

Dr. Muzaffar's primary practice is ECU Health Medical Center, at 2100 Stantonsburg Rd, Greenville, NC 27834 in Pitt County. The practice phone is (252) 847-4100.

Dr. Muzaffar's primary practice is ECU Health Medical Center in Greenville, North Carolina, part of University Health Systems of Eastern Carolina. The medical group on file is ECU Health. Dmand AI also links Dr. Muzaffar to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Muzaffar practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Muzaffar's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Muzaffar is licensed in North Carolina.

CMS data shows 656 Medicare services from Dr. Muzaffar across 8 procedure codes in 2024, for 196 Medicare patients. Medicare paid $52,454 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 196 Medicare patients who saw Dr. Muzaffar in 2024. The largest group is 65 to 74, with 93 patients. 75% of them have high blood pressure, and 71% have high cholesterol. 17% are also on Medicaid. Their average risk score is 2.48, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Muzaffar's median patient age at 71, with 75% women.

In 2024, Dr. Muzaffar wrote 510 Medicare Part D claims for 126 patients. 77% of them were for generic drugs. CMS names the drug for 349 of them, across 12 drugs with 11 or more claims each, at $522,251 in total drug cost. In 2023, CMS named 622 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Muzaffar for performance year 2024, reported through an alternative payment model (APM). Dr. Muzaffar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Muzaffar as offering telehealth.

Dmand AI links 52 papers to Dr. Muzaffar, published from 2010 to 2024. 2022 was the busiest year, with 7. The most frequent topics are Breast Neoplasms, Carcinoma, Hepatocellular and Liver Neoplasms. Dr. Muzaffar has published most often in Am J Ther. Dr. Muzaffar's most frequent co-authors are Thomas Urban Marron, MD, PhD, Uqba Khan, MD and Nasreen A. Vohra, MD.

Dmand AI links Dr. Muzaffar to 9 clinical trials, 7 of them phase 3 studies. 7 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Brain Neoplasms. Alliance for Clinical Trials in Oncology sponsors the most, 4.

CMS Open Payments shows 492 general payments to Dr. Muzaffar from 54 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 94% of the total. Novartis Pharmaceuticals Corporation paid the most, $730.